All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What impact does osseous vs hematogenous extramedullary MM have on patient outcomes?
Featured
Bookmark this article
The Multiple Myeloma Hub was pleased to speak to Sergio Rodriguez-Rodriguez, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MX. We asked, What impact does osseous vs hematogenous extramedullary multiple myeloma (EMM) have on patient outcomes?
What impact does osseous vs hematogenous extramedullary MM have on patient outcomes?
In this video interview, Sergio Rodriguez-Rodriguez discusses the outcomes associated with osseous and hematogenous EMM in a cohort of patients treated in Mexico. Rodriguez opens by explaining how osseous and hematogenous EMM manifests in patients and the associated poor prognoses. Rodriguez goes on to highlight the treatment landscape in Mexico, including limited access to novel interventions, as confounding factors influencing these outcomes.
This expert interview is also available in Spanish.
Your opinion matters
30 votes - 2 days left ...
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox